VVVictor Valcour

Victor Valcour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Victor Valcour has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew E Williams

    D Kaiser Permanente, Honolulu, Hawaii

    3 shared publications
  • Cecilia Shikuma

    Hawaii AIDS Clinical Research Program, University of Hawaii at Manoa, Honolulu, HI 96816

    3 shared publications
  • B. Shiramizu

    University of Hawaii NeuroAIDS Specialized Neuroscience Research Program, John A. Burns School of Medicine, Honolulu, HI, United States

    2 shared publications
  • B. T. Shiramizu

    From the Hawaii AIDS Clinical Research Program (V.G.V., B.T.S., S.R.-K., J.A., J.H.K., C.M.S.), John A. Burns School of Medicine, University of Hawaii, Honolulu; Memory and Aging Center (V.G.V.), Department of Neurology, University of California, San Francisco; Division of Neurology (P.S., S.N.), Department of Medicine, Phramongkutklao Hospital, Bangkok; Department of Retrovirology (S.R.-K., J.H.K., M.d.S.), Armed Forces Research Institute of Medical Sciences, Bangkok; Southeast Asia Research...

    2 shared publications
  • Bruce Shiramizu

    Hawaii AIDS Clinical Research Program, University of Hawaii at Manoa, Honolulu, HI 96816

    2 shared publications
  • C. M. Shikuma

    From the Hawaii AIDS Clinical Research Program (V.G.V., B.T.S., S.R.-K., J.A., J.H.K., C.M.S.), John A. Burns School of Medicine, University of Hawaii, Honolulu; Memory and Aging Center (V.G.V.), Department of Neurology, University of California, San Francisco; Division of Neurology (P.S., S.N.), Department of Medicine, Phramongkutklao Hospital, Bangkok; Department of Retrovirology (S.R.-K., J.H.K., M.d.S.), Armed Forces Research Institute of Medical Sciences, Bangkok; Southeast Asia Research...

    2 shared publications

Latest Publications

  • HIV DNA and cognition in a Thai longitudinal HAART initiation cohort

    by V. G. Valcour, B. T. Shiramizu, P. Sithinamsuwan, S. Nidhinandana, S. Ratto-Kim, J. Ananworanich, U. Siangphoe, J. H. Kim, M. de Souza, V. Degruttola, et al.

    Objectives: The extent to which highly active antiretroviral therapy (HAART) era cognitive disorders are due to active processes, incomplete clearance of reservoirs, or comorbidities is controversial. This study aimed to determine if immunologic and virologic factors influence cognition after first-time HAART in Thai individuals with HIV-associated dementia (HAD) and Thai individuals without HAD (non-HAD). Methods: Variables were captured longitudinally to determine factors predictive of degree of cognitive recovery after first-time HAART. Neuropsychological data were compared to those of 230 HIV-negative Thai controls. Results: HIV RNA and CD4 lymphocyte counts were not predictive of HAD cross-sectionally or degree of cognitive improvement longitudinally. In contrast, baseline and longitudinal HIV DNA isolated from monocytes correlated to cognitive performance irrespective of plasma HIV RNA and CD4 lymphocyte counts pre-HAART (p < 0.001) and at 48 weeks post HAART (p < 0.001). Levels exceeding 3.5 log10 copies HIV DNA/106 monocyte at baseline distinguished all HAD and non-HAD cases (p < 0.001). At 48 weeks, monocyte HIV DNA was below the level of detection of our assay (10 copies/106 cells) in 15/15 non-HAD compared to only 4/12 HAD cases, despite undetectable plasma HIV RNA in 26/27 cases. Baseline monocyte HIV DNA predicted 48-week cognitive performance on a composite score, independently of concurrent monocyte HIV DNA and CD4 count (p < 0.001). Conclusions: Monocyte HIV DNA level correlates to cognitive performance before highly active antiretroviral therapy (HAART) and 48 weeks after HAART in this cohort and baseline monocyte HIV DNA may predict 48-week cognitive performance. These findings raise the possibility that short-term incomplete cognitive recovery with HAART may represent an active process related to this peripheral reservoir.


  • Open Access

    Acetyl‐l‐carnitine and nucleoside reverse transcriptase inhibitor‐associated neuropathy in HIV infection

    by V Valcour, T-M Yeh, R Bartt, D Clifford, M Gerschenson, Sr Evans, Ba Cohen, Gj Ebenezer, P Hauer, L Millar, et al.

    Objectives: Antiretroviral toxic neuropathy (ATN) is associated with dideoxynucleoside reverse transcriptase inhibitor use in patients infected with HIV, possibly as a result of mitochondrial toxicity. Acetyl‐l‐carnitine (ALC) has been linked to symptomatic improvement in ATN. We present an open‐label single‐arm pilot study to evaluate changes in intra‐epidermal nerve fibre (IENF) density and mitochondrial DNA (mtDNA) copies/cell among subjects treated with 3000 mg ALC daily.Methods: Punch skin biopsies were examined at baseline and after 24 weeks of therapy. Participants reported neuropathic symptoms using the Gracely Pain Intensity Score. Neurological examinations were completed.Results: Twenty‐one subjects completed the study. ALC was generally well tolerated. The IENF density did not change in cases completing 24 weeks of ALC therapy, with median (90% confidence interval) IENF changes of −1.70 (−3.50, ∞) (P=0.98) and 2.15 (−0.10, ∞) (P=0.11) for the distal leg and proximal thigh, respectively. Fat mtDNA copies/cell did not change with therapy. Improvements in neuropathic pain (PP=0.01), and symptoms of numbness (P<0.01) were noted. Similarly, improvement was noted on the Gracely Pain Intensity Score.Conclusions: ALC therapy coincided with improvements in subjective measures of pain in this open‐label single‐arm study. However, changes were not observed in objective measures of IENF density or mtDNA levels, providing little objective support for use of ALC in this setting.


  • Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy

    by Victor Valcour, Michael R. Watters, Andrew E Williams, Ned Sacktor, Aaron McMurtray, Cecilia Shikuma

    The phenotype of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) in the developed world has changed with the broad institutio


  • Neuropsychological abnormalities in patients with dementia in CRF 01_AE HIV-1 infection

    by V. G. Valcour, P. Sithinamsuwan, S. Nidhinandana, S. Thitivichianlert, S. Ratto-Kim, W. Apateerapong, B. T. Shiramizu, M. S. Desouza, S. T. Chitpatima, G. Watt, et al.

    HIV-associated dementia (HAD) is not firmly established in patients with circulating recombinant form (CRF) 01_AE HIV-1. In this study, we compared neuropsychological performance among 15 Thai individuals with HAD, 15 Thai individuals without HAD, and 30 HIV-negative control subjects. HIV-1 participants were highly active anti-retroviral therapy naive and matched by age, education, and CD4 count. Neuropsychological testing abnormalities were identified in most cognitive domains among HAD vs HIV-negative participants, confirming the presence of HAD in CRF01_AE.


  • Insulin Resistance Is Associated With Cognition Among HIV-1-Infected Patients

    by Victor G Valcour, Ned C Sacktor, Robert H Paul, Michael R Watters, Ola A Selnes, Bruce T Shiramizu, Andrew E Williams, Cecilia M Shikuma

    To determine if insulin resistance (IR) is associated with lower cognitive performance among HIV-1-infected adults and to determine if advanced age magnifies risk. Cross-sectional analysis within the Hawaii Aging With HIV Cohort. We calculated the homeostasis model assessment of insulin resistance (HOMA-IR) among 145 cohort participants. Values were compared to concurrent neuropsychological test performance and cognitive diagnoses. Hypertension, body mass index (BMI), and non-Caucasian self-identity were directly related to insulin resistance (IR); however, age, CD4 lymphocyte count, and rates of treatment with HAART were not. In logistic regression analyses and stratifying cognition status on a 3-tiered scale (normal, minor cognitive motor disorder (MCMD), and HIV-associated dementia (HAD)), we identified an increased risk of meeting a higher diagnostic category as HOMA-IR increased (OR, 1.12; 95% CI: 1.003 to 1.242 per unit of HOMA-IR, P = 0.044). In linear regression models and among nondiabetic participants, an increasing degree of IR was associated with lower performance on neuropsychological summary scores. IR is associated with cognitive dysfunction in this contemporary HIV-1 cohort enriched with older individuals. Metabolic dysfunction may contribute to the multifactorial pathogenesis of cognitive impairment in the era of HAART.


  • Open Access

    HIV Infection and Dementia in Older Adults

    by Kevin P. High, Victor Valcour, Robert Paul

    Human immunodeficiency virus (HIV) infection in older patients is becoming increasingly common as seropositive individuals live longer because of lon


  • Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection—The Hawaii Aging with HIV Cohort

    by Victor Valcour, Priscilla Yee, Andrew E Williams, Bruce Shiramizu, Michael Watters, Ola Selnes, Robert Paul, Cecilia Shikuma, Ned Sacktor

    Low CD4 lymphocyte count was a marker for neurological disease in human immunodeficiency virus type 1 (HIV-1); but is now less common among patients with access to highly active antiretroviral...


  • Diabetes, Insulin Resistance, and Dementia Among HIV-1-Infected Patients

    by Victor G. Valcour, Cecilia M. Shikuma, Bruce T. Shiramizu, Andrew E. Ma Williams, Michael R. Watters, Pamela W. Poff, John S. Grove, Ola A. Selnes, Ned C. Sacktor

    Objectives: Metabolic complications have been associated with HIV-1 infection and with long-term use of antiretroviral (ARV) medications. In some studies, such complications have been linked to cardiovascular events, yet limited data exist concerning metabolic complications and dementia. The objective of this study was to examine the relationship between HIV-associated dementia (HAD) and diabetes among patients with HIV-1 infection. Design: Cross-sectional analysis of entry data for a longitudinal cohort study. Methods: A total of 203 participants who were enrolled in the Hawaii Aging with HIV Cohort between October 2001 and November 2003 served as the study population. Research case definitions of HAD were determined in consensus conferences by a panel that included neurologists, neuropsychologists, and a geriatrician. Diabetes was determined by self-report or a fasting glucose level > 125 mg/dL. Results: Participants' ages ranged between 20-76 years at enrollment with approximately one-half aged ≥50 years. After adjustment for important covariates including age, education, ethnicity, CD4 lymphocyte count, duration of HIV infection, and protease inhibitor-based ARV therapy, we found a statistically significant association of diabetes with HAD (odds ratio 5.43, 1.66-17.70). A significant association remained after adjustment for other vascular risk factors. Among participants without diabetes, fasting glucose levels were higher with increasing impairment category. Conclusions: Within the Hawaii Aging with HIV Cohort, a longitudinal study enriched with older HIV-1-infected individuals, diabetes is associated with prevalent dementia. This finding is not fully explained by age or coexisting vascular risk factors. Evaluation of underlying mechanisms is warranted.